Immunovant's total assets for Q1 2026 were $661.44M, a decrease of -14.79% from the previous quarter. IMVT total liabilities were $52.90M for the fiscal quarter, a -23.08% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.